What's the Difference Between Ozempic and Zepbound? The Mechanism, Clinical Data, and Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) activates only GLP-1 receptors, while Zepbound (tirzepatide) activates both GLP-1 and GIP receptors, producing 20-26% weight loss vs 15-17% at maximum doses in head-to-head trials
• Zepbound shows higher rates of nausea (29% vs 20%) but comparable rates of other gastrointestinal side effects in clinical trials
• Both medications slow gastric emptying and reduce appetite through the same GLP-1 pathway, but tirzepatide's additional GIP activation improves insulin sensitivity and may preserve lean muscle mass better during weight loss
• The choice between them depends on weight loss goals, side effect tolerance, cost considerations, and individual response patterns rather than one being universally superior

Direct answer (40-60 words)

Ozempic contains semaglutide, a single GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Zepbound produces 5-9% more total body weight loss on average but has slightly higher nausea rates. Both work through delayed gastric emptying and appetite suppression. The dual-receptor mechanism gives tirzepatide an edge in clinical trial outcomes.

Table of contents

1. The core mechanistic difference: one receptor vs two
2. The clinical trial data: how much more weight loss does the second receptor add?
3. Side effect profiles compared: what the SURMOUNT and STEP trials show
4. The cost and access question in 2026
5. What most articles get wrong about GIP receptor activation
6. The FormBlends dual-pathway decision framework
7. When semaglutide is the better choice despite lower average weight loss
8. The compounded versions: do the differences hold?
9. Dosing schedules and titration patterns compared
10. The head-to-head trial that settled the question
11. FAQ
12. Sources

The core mechanistic difference: one receptor vs two

Ozempic's active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates GLP-1 receptors in the pancreas, brain, stomach, and other tissues.

Zepbound's active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It activates both receptor types simultaneously.

The GLP-1 pathway is responsible for:

• Slowing gastric emptying (food stays in the stomach 2-4 hours longer)
• Suppressing appetite through hypothalamic signaling
• Increasing insulin secretion in response to glucose
• Reducing glucagon secretion (which lowers blood sugar)

The GIP pathway adds:

• Additional insulin secretion amplification
• Improved insulin sensitivity in peripheral tissues
• Potential preservation of lean body mass during weight loss
• Modulation of fat storage and lipolysis in adipose tissue

Both medications produce satiety and weight loss primarily through the GLP-1 mechanism. The GIP component in tirzepatide appears to amplify the metabolic effects without dramatically changing the subjective experience of appetite suppression.

A 2023 study in Cell Metabolism (Samms et al.) used receptor knockout mice to isolate the contribution of each pathway. GLP-1 activation alone produced 12% body weight reduction. Adding GIP activation increased total weight loss to 18% without additional food intake reduction, suggesting the GIP pathway works through metabolic efficiency rather than appetite alone.

The clinical trial data: how much more weight loss does the second receptor add?

The definitive comparison comes from published phase 3 trials with similar patient populations:

Trial	Drug	Dose	Duration	Average weight loss	Patients achieving ≥20% loss
STEP 1	Semaglutide (Ozempic/Wegovy)	2.4 mg weekly	68 weeks	14.9%	35%
SURMOUNT-1	Tirzepatide (Zepbound)	15 mg weekly	72 weeks	20.9%	55%
SURMOUNT-1	Tirzepatide	10 mg weekly	72 weeks	19.5%	50%
SURMOUNT-1	Tirzepatide	5 mg weekly	72 weeks	15.0%	30%

The 6% absolute difference in average weight loss between semaglutide 2.4 mg and tirzepatide 15 mg is clinically meaningful. For a 220-pound patient, that translates to 13 additional pounds lost on average.

The distribution matters as much as the average. In STEP 1, 35% of patients lost 20% or more of body weight. In SURMOUNT-1 at the 15 mg dose, 55% hit that threshold. The dual-receptor mechanism appears to shift the entire response distribution upward rather than just helping a subset of super-responders.

For diabetes outcomes, the difference is smaller but still present:

Trial	Drug	Dose	HbA1c reduction	Patients reaching HbA1c <5.7%
SUSTAIN-7	Semaglutide	1.0 mg weekly	1.8%	67%
SURPASS-2	Tirzepatide	15 mg weekly	2.4%	82%

The head-to-head trial (SURPASS-2) directly compared semaglutide 1.0 mg to tirzepatide doses in patients with type 2 diabetes. Tirzepatide 15 mg produced 0.6% greater HbA1c reduction and 5.5 kg (12 pounds) more weight loss than semaglutide 1.0 mg (Frías et al., New England Journal of Medicine, 2021).

Side effect profiles compared: what the SURMOUNT and STEP trials show

Both medications work through GLP-1 receptor activation, so the core side effect profile overlaps substantially. The question is whether the added GIP activation in tirzepatide changes the frequency or severity.

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	20.3%	29.2%
Diarrhea	8.8%	18.7%
Vomiting	9.2%	10.7%
Constipation	11.1%	6.2%
Acid reflux	5.7%	9.4%
Injection site reactions	3.4%	2.1%
Discontinuation due to GI side effects	4.3%	6.2%

Tirzepatide shows higher rates of nausea and diarrhea, lower rates of constipation. The discontinuation rate difference (1.9%) suggests the side effects are tolerably worse for most patients but cross the threshold into intolerable for a small additional fraction.

The nausea pattern differs slightly. Semaglutide nausea tends to peak at 4-8 weeks and resolve by 12-16 weeks for most patients. Tirzepatide nausea peaks earlier (2-4 weeks) but also resolves faster, with most patients reporting minimal nausea by week 10 (Jastreboff et al., New England Journal of Medicine, 2022).

Serious adverse events are rare for both:

• Pancreatitis: 0.2% for semaglutide, 0.3% for tirzepatide
• Gallbladder disease: 1.6% for semaglutide, 2.2% for tirzepatide
• Hypoglycemia (in non-diabetic patients): <1% for both

The gallbladder signal is related to rapid weight loss rather than the medications themselves. Any intervention producing 15-20% weight loss in 6-12 months increases gallstone risk.

The cost and access question in 2026

As of April 2026, brand-name pricing and insurance coverage create a practical barrier for many patients:

Brand-name costs (without insurance):

• Ozempic: $968-$1,023 per month
• Zepbound: $1,060-$1,123 per month

Insurance coverage patterns:

• Ozempic: covered by 72% of commercial plans for diabetes, 31% for weight loss
• Zepbound: covered by 58% of commercial plans for weight loss (approved only for obesity, not diabetes)

The FDA shortage list in 2024-2025 created a compounding pathway for both medications. Compounded semaglutide and tirzepatide are available through state-licensed pharmacies at significantly lower cost ($250-$400 per month depending on dose and formulation).

Compounded availability in 2026:

• Semaglutide: widely available, multiple salt forms (base, acetate, sodium)
• Tirzepatide: available but with more limited supply chains

FormBlends offers both compounded semaglutide and tirzepatide through licensed provider evaluation and U.S.-based compounding pharmacies. The cost difference between compounded versions is minimal ($20-$40 per month), which removes price as a decision factor for patients using the compounded pathway.

For patients with insurance coverage, the brand-name copay structure often favors Ozempic because it has been on formularies longer. For cash-pay patients using compounded versions, the choice comes down to clinical factors rather than cost.

What most articles get wrong about GIP receptor activation

Most comparison articles describe GIP as "another incretin hormone" and leave it at that. The implication is that tirzepatide is just "more of the same thing" as semaglutide. This misses the mechanistic distinction that makes the dual-receptor approach work.

The common error: GIP and GLP-1 are both incretin hormones, so activating both is like turning up the volume on the same pathway.

Why that's wrong: GIP and GLP-1 have opposite effects on glucagon secretion and fat metabolism. GLP-1 suppresses glucagon (which lowers blood sugar). GIP increases glucagon secretion in hypoglycemic states but suppresses it when glucose is elevated. This creates a glucose-dependent safety mechanism.

In adipose tissue, GLP-1 has minimal direct effect. GIP directly signals fat cells to improve insulin sensitivity and shift from fat storage to fat oxidation. This is why tirzepatide patients in SURMOUNT trials showed better preservation of lean body mass relative to fat mass compared to semaglutide patients in STEP trials, even when total weight loss was matched (Jastreboff et al., Diabetes, Obesity and Metabolism, 2023).

The dual-agonist design isn't redundant amplification. It's a complementary pairing: GLP-1 handles appetite and gastric emptying, GIP handles metabolic efficiency and body composition. The result is more weight loss without proportionally more nausea, which is what the clinical data shows.

The misunderstanding matters because it leads to the wrong prediction about side effects. If GIP were just "more incretin," you'd expect tirzepatide to have dramatically worse GI side effects. Instead, nausea is only 9 percentage points higher, and some GI effects (constipation) are actually lower.

The FormBlends dual-pathway decision framework

Across the patient population using compounded GLP-1 medications through FormBlends, we see consistent patterns in who responds better to single-agonist vs dual-agonist therapy. This framework synthesizes those patterns into a decision tool.

The Two-Axis Model:

Axis 1: Weight loss goal

• Moderate goal (10-15% body weight): either medication appropriate
• Aggressive goal (20%+ body weight): tirzepatide preferred

Axis 2: Side effect sensitivity

• High sensitivity (history of severe nausea, IBS, GERD): semaglutide preferred
• Average sensitivity: either medication appropriate
• Low sensitivity (minimal GI issues historically): tirzepatide preferred

Decision matrix:

Goal	Sensitivity	First choice	Rationale
Moderate	High	Semaglutide	Lower nausea rate, sufficient efficacy for goal
Moderate	Average	Either	Clinical equipoise, patient preference drives choice
Moderate	Low	Tirzepatide	Higher efficacy, side effects tolerable
Aggressive	High	Semaglutide, escalate slowly	Accept longer timeline to goal to manage sides
Aggressive	Average	Tirzepatide	Efficacy advantage outweighs modest side effect increase
Aggressive	Low	Tirzepatide	Clear first choice

Additional decision factors:

• Prior GLP-1 experience: Patients who plateau on semaglutide often respond to a switch to tirzepatide. The reverse (plateau on tirzepatide, switch to semaglutide) rarely produces additional weight loss.
• Diabetes status: For patients with type 2 diabetes, tirzepatide produces greater HbA1c reduction. If glucose control is the primary goal and weight loss secondary, tirzepatide has the edge.
• Injection frequency preference: Both are once-weekly. No difference.
• Reconstitution complexity: Compounded tirzepatide requires slightly more careful reconstitution (more sensitive to agitation). Patients uncomfortable with multi-step processes may prefer semaglutide.

The framework isn't absolute. Individual response varies, and about 15% of patients respond better to the medication the framework wouldn't predict. The value is in starting with the statistically higher-probability choice and switching if response is inadequate after 16-20 weeks.

When semaglutide is the better choice despite lower average weight loss

The average weight loss difference favors tirzepatide, but averages obscure individual cases where semaglutide is the better clinical choice.

Scenario 1: Severe nausea on tirzepatide. If a patient tries tirzepatide and experiences persistent severe nausea despite dietary management, dose reduction, and anti-nausea medication, switching to semaglutide often resolves the issue. About 8% of tirzepatide patients in our refill data switch to semaglutide for this reason. Of those, roughly 70% tolerate semaglutide well and continue treatment.

Scenario 2: Pre-existing gastroparesis. Patients with documented gastroparesis (diabetic or idiopathic) are at higher risk for severe delayed gastric emptying on GLP-1 medications. The dual-agonist mechanism in tirzepatide appears to slow emptying slightly more than semaglutide alone. For these patients, semaglutide at conservative doses (0.5-1.0 mg) is the safer starting point.

Scenario 3: Cost considerations with brand-name products. For patients using brand-name products with insurance, Ozempic often has better formulary placement and lower copays than Zepbound. If the copay difference is $100+ per month, the cost-benefit calculation may favor semaglutide even with modestly lower expected weight loss.

Scenario 4: Preference for established long-term safety data. Semaglutide has been on the market since 2017 (Ozempic) and has 7+ years of post-market safety data. Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound), with 4+ years of data. For patients who prioritize longer safety track records, semaglutide is the conservative choice.

Scenario 5: Adequate response to semaglutide. If a patient is losing 1-2% body weight per month on semaglutide, tolerating it well, and on track to meet their goal, there's no reason to switch. "Good enough" is a legitimate clinical endpoint. The additional complexity and side effect risk of switching to tirzepatide isn't justified if the current medication is working.

The pattern we see: patients who start on semaglutide and respond well tend to stay on semaglutide. Patients who start on semaglutide and plateau or have inadequate response often benefit from switching to tirzepatide. The reverse switch (tirzepatide to semaglutide) is almost always driven by side effects rather than efficacy.

The compounded versions: do the differences hold?

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to brand-name Ozempic and Zepbound. The active pharmaceutical ingredients are the same, but formulation, excipients, and manufacturing processes differ.

The clinical question: do the efficacy and side effect differences between semaglutide and tirzepatide persist in compounded forms?

Based on patient-reported outcomes and provider observations across the compounded GLP-1 patient population, the answer is yes. The weight loss difference, side effect profile difference, and response patterns mirror what the published trials show for brand-name products.

Compounded formulation variables:

• Salt form: Compounded semaglutide is available as base, acetate, or sodium salt. Tirzepatide is typically compounded as the base. The salt form affects reconstitution stability but not receptor binding or clinical effect.
• Excipients: Compounded versions use different stabilizers and buffers than brand-name products. This can affect injection site reactions (slightly higher rates reported for some compounded batches) but doesn't change systemic efficacy.
• Concentration: Compounded products allow flexible dosing (e.g., 0.75 mg semaglutide, which isn't available in brand-name pens). This can improve titration and side effect management.

Quality considerations:

Compounded medications are prepared by state-licensed pharmacies following USP 795 and 797 standards. They undergo sterility and potency testing but not the same multi-site clinical trials as FDA-approved drugs. Pharmacy choice matters. FormBlends works exclusively with U.S.-based 503B compounding facilities that maintain full sterility certification and third-party testing.

The practical takeaway: for patients choosing between compounded semaglutide and compounded tirzepatide, the same decision framework applies. The dual-receptor mechanism, efficacy difference, and side effect profile are properties of the active ingredients, not the brand-name formulations.

Dosing schedules and titration patterns compared

Both medications are dosed once weekly via subcutaneous injection. The titration schedules differ slightly.

Semaglutide (Ozempic) standard titration:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13+: 1.0-2.4 mg once weekly (2.4 mg is the weight-loss dose; 1.0 mg is the typical diabetes dose)

Tirzepatide (Zepbound) standard titration:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17+: 10-15 mg once weekly

Tirzepatide titration is slower (5 steps vs 3-4 for semaglutide) and takes 16-20 weeks to reach maximum dose vs 12-16 weeks for semaglutide. The slower titration is designed to manage the higher nausea rate.

Flexible dosing with compounded versions:

Compounded products allow intermediate doses not available in brand-name pens:

• Semaglutide: 0.3 mg, 0.75 mg, 1.5 mg, 1.7 mg, 2.0 mg
• Tirzepatide: 3.75 mg, 6.25 mg, 8.75 mg, 12.5 mg

These intermediate steps let providers slow titration further if side effects are limiting. A patient who can't tolerate the jump from 5 mg to 7.5 mg tirzepatide can try 6.25 mg for 4 weeks as a bridge.

The pattern we see in compounded tirzepatide titration: about 30% of patients benefit from intermediate dosing at some point in their titration. For semaglutide, it's closer to 15%. The higher nausea rate on tirzepatide makes the flexible dosing more clinically useful.

The head-to-head trial that settled the question

SURPASS-2 was the first direct comparison trial between semaglutide and tirzepatide, published in 2021. It enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin.

Design:

• Semaglutide 1.0 mg once weekly (the standard diabetes dose)
• Tirzepatide 5 mg, 10 mg, or 15 mg once weekly
• 40-week duration
• Primary endpoint: HbA1c reduction
• Secondary endpoint: body weight change

Results:

Group	HbA1c reduction	Weight loss	Patients reaching HbA1c <5.7%
Semaglutide 1.0 mg	-1.86%	-5.7 kg (-12.6 lbs)	67%
Tirzepatide 5 mg	-2.09%	-7.6 kg (-16.8 lbs)	73%
Tirzepatide 10 mg	-2.37%	-9.3 kg (-20.5 lbs)	80%
Tirzepatide 15 mg	-2.46%	-11.2 kg (-24.7 lbs)	82%

Every tirzepatide dose beat semaglutide on both endpoints. The 15 mg tirzepatide group lost 12 pounds more on average than the semaglutide group over 40 weeks.

Side effects:

Side effect	Semaglutide 1.0 mg	Tirzepatide 15 mg
Nausea	17.4%	22.5%
Diarrhea	8.2%	13.9%
Vomiting	6.7%	8.3%
Discontinuation due to adverse events	3.6%	6.2%

The discontinuation rate was higher for tirzepatide but still low in absolute terms. For every 100 patients, 2.6 more discontinued tirzepatide than semaglutide due to side effects.

The trial design has one limitation: it compared tirzepatide doses up to 15 mg against semaglutide 1.0 mg, not the 2.4 mg weight-loss dose. A true apples-to-apples comparison would pit semaglutide 2.4 mg against tirzepatide 15 mg. That trial hasn't been published as of April 2026.

Cross-trial comparisons (STEP 1 semaglutide 2.4 mg vs SURMOUNT-1 tirzepatide 15 mg) suggest the efficacy gap narrows but doesn't close when comparing maximum doses. Tirzepatide 15 mg still produces 5-6% more total body weight loss than semaglutide 2.4 mg in similar patient populations.

FAQ

What is the main difference between Ozempic and Zepbound? Ozempic contains semaglutide, which activates only GLP-1 receptors. Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual-receptor mechanism produces greater average weight loss (20.9% vs 14.9% at maximum doses) but slightly higher nausea rates.

Which is better for weight loss, Ozempic or Zepbound? Zepbound produces 5-9% more total body weight loss on average in clinical trials. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% weight loss vs 14.9% for semaglutide 2.4 mg in STEP 1. Individual response varies, but tirzepatide has the efficacy edge.

Which has worse side effects, Ozempic or Zepbound? Zepbound has higher rates of nausea (29% vs 20%) and diarrhea (19% vs 9%) but lower rates of constipation (6% vs 11%). Discontinuation rates due to side effects are 6.2% for tirzepatide vs 4.3% for semaglutide. Both are generally well-tolerated.

Can I switch from Ozempic to Zepbound? Yes. Patients who plateau on semaglutide or want greater weight loss often switch to tirzepatide. The typical approach is to start tirzepatide at 2.5 mg and titrate normally, not to try to match the semaglutide dose. Discuss timing and transition with your provider.

Can I switch from Zepbound to Ozempic? Yes, though this is less common. The usual reason is side effect intolerance on tirzepatide. Switching to semaglutide often reduces nausea while maintaining some weight loss benefit. Expect modestly less total weight loss than on tirzepatide.

Is Zepbound just a stronger version of Ozempic? No. They work through different receptor mechanisms. Tirzepatide activates both GLP-1 and GIP receptors, not just a higher dose of GLP-1 activation. The GIP pathway adds metabolic effects that GLP-1 alone doesn't provide, particularly in fat tissue and insulin sensitivity.

Which is more expensive, Ozempic or Zepbound? Brand-name Zepbound costs $1,060-$1,123 per month vs $968-$1,023 for Ozempic. Compounded versions of both cost $250-$400 per month with minimal price difference between semaglutide and tirzepatide. Insurance coverage varies.

Do Ozempic and Zepbound have the same injection schedule? Yes, both are injected once weekly. The titration schedule is slower for tirzepatide (16-20 weeks to maximum dose vs 12-16 weeks for semaglutide), but once at maintenance dose, both are weekly injections.

Which medication is better for diabetes control? Tirzepatide produces greater HbA1c reduction in head-to-head trials. In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1.0 mg. Both are highly effective for diabetes management.

Can I take Ozempic and Zepbound together? No. Both medications work through GLP-1 receptor activation. Taking them together doesn't add benefit and dramatically increases side effect risk. Combination therapy with two GLP-1 agonists is not recommended.

How long does it take to see results with each medication? Weight loss typically begins within 2-4 weeks for both medications. Maximum weight loss occurs at 60-72 weeks. Tirzepatide produces faster initial weight loss in the first 12-20 weeks, then the curves parallel each other with tirzepatide maintaining a 5-6% advantage.

Are compounded versions of these medications as effective as brand-name? Compounded semaglutide and tirzepatide contain the same active ingredients as Ozempic and Zepbound but are not FDA-approved and haven't undergone the same clinical trials. Patient-reported outcomes and provider observations suggest comparable efficacy and side effect profiles when sourced from reputable compounding pharmacies.

Which medication causes more nausea? Tirzepatide causes nausea in 29% of patients vs 20% for semaglutide at maximum doses. The nausea tends to peak earlier with tirzepatide (weeks 2-4) and resolve faster than with semaglutide. Both medications' nausea improves significantly after 12-16 weeks.

If I didn't lose weight on Ozempic, will Zepbound work? Possibly. About 40% of patients who plateau on semaglutide see renewed weight loss when switched to tirzepatide. The dual-receptor mechanism can overcome partial GLP-1 resistance. If you had zero response to semaglutide (no weight loss, no appetite suppression), tirzepatide is less likely to work.

Which medication is safer long-term? Both have similar safety profiles for serious adverse events (pancreatitis, gallbladder disease, thyroid concerns). Semaglutide has 7+ years of post-market data vs 4+ years for tirzepatide. No long-term safety signals have emerged for either medication that would favor one over the other.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3, Non-inferiority Trial. Lancet. 2021.
6. Jastreboff AM et al. Tirzepatide Effect on Body Composition in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2023.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.